Esophageal Cancer
Conditions
Interventions
Sponsors
Wuwei Tumor Hospital Heavy Ion Center
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. The pathology confirmed squamous or adenocarcinoma ; 2. AJCC 2017 8th Edition CT1-4 any N M0; 3. No distant metastasis to solid organs; 4. Never received radiation therapy for esophageal cancer; 5. No history of other malignant tumors (except cured skin cancer and stage zero cervical cancer); 6. Renal function, liver function and bone marrow function were basically normal (serum creatinine9.5 g/dL; White blood cell count>=3000 /ml; Platelet count>= 100,000 /mL); 7. Aged from 18 to 80 years; 8. Good physical condition, ECOG (Eastern United States Collaborative Oncology Group) =6 months. 10. Prior to radiotherapy, the patient or his/her legal representative has signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with esophageal tracheal fistula or who have been judged by physicians to be at high risk of esophageal tracheal fistula; 2. Weight loss of more than 20% within six months; 3. Pregnancy (confirmed by serum or urine ß-HCG test) or lactation period; 4. Drug or alcohol abuse; 5. AIDS patients; 6. Concomitant with uncontrolled systemic, pulmonary or heart disease; 7. Concomitant serious comorbidities, including uncontrolled comorbidities (pulmonary insufficiency, cardiovascular, lung, liver, kidney, diabetes, etc.), addiction, and/or mental illness that prevent the trial regimen from proceeding smoothly; 8. Implant pacemaker or other metal prosthesis enough to affect radiotherapy; 9. Patients with poor compliance, including the possibility of failing to complete the treatment plan or receiving the required follow-up and testing check; 10. Previous experience with other malignant tumors (except non-malignant melanoma skin cancer or non-invasive cervical cancer); 11. Simultaneously receiving systemic immunotherapy or corticosteroid therapy; 12. Serum creatinine clearance rate < 30ml/ min; 13. Contraindications to radiotherapy; 14. Participated in other drug clinical trials within 30 days prior to inclusion in this study; 15. Incapacity or limited capacity for civil conduct; 16. Any medical history that, in the investigator's judgment, may interfere with trial results or increase patient risk; 17. Any circumstances in which the physician deems it inappropriate to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Local contral rate of tumor;Tumor response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Median progression-free survival;Overall survival;Distant metastasis rate; | — |
Countries
China
Contacts
Public ContactZhang Yanshan
Wuwei Tumor Hospital Heavy Ion Center
Outcome results
None listed